Trial Profile
A trial to investigate the efficacy of GKT137831 for the treatment of systemic sclerosis
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2015
Price :
$35
*
At a glance
- Drugs Setanaxib (Primary)
- Indications Systemic scleroderma
- Focus Therapeutic Use
- 10 Sep 2015 New trial record
- 09 Sep 2015 According to a Genkyotex media release, this trial is expected to begin in 2016.